Abivax (ABVX) Current Assets (2022 - 2026)

Abivax's Current Assets history runs 5 years deep, the most recent figure standing at $600.9 million for Q1 2026.

• In Q1 2026, Current Assets rose 330.56% year-over-year to $600.9 million; the TTM figure through Mar 2026 stood at $600.9 million (up 330.56% YoY), while the FY2025 annual figure was $641.7 million, up 251.84% from the prior year.
• Current Assets was $600.9 million for Q1 2026 at Abivax, down from $641.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $724.0 million in Q3 2025 to a low of $36.9 million in Q4 2022.
• Historically, Current Assets has averaged $332.5 million across 5 years, with a median of $261.7 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Current Assets jumped 733.54% in 2023, then sank 62.75% in 2025.
• A 5-year view of Current Assets shows it stood at $36.9 million in 2022, then surged by 733.54% to $307.7 million in 2023, then slumped by 40.73% to $182.4 million in 2024, then surged by 251.84% to $641.7 million in 2025, then dropped by 6.36% to $600.9 million in 2026.
• The last three Current Assets figures came in at $600.9 million (Q1 2026), $641.7 million (Q4 2025), and $724.0 million (Q3 2025), per Business Quant data.